857200-26-1

Basic information

• Product Name: 2-(methylthio)-4-(phenylamino)pyrimidine-5-carboxylicacid
• Synonyms: 2-(methylthio)-4-(phenylamino)pyrimidine-5-carboxylicacid;2-(methylthio)-4-(phenylamino)-5-pyrimidinecarboxylic acid
• CAS NO: 857200-26-1
• Molecular Formula: C₁₂H₁₁N₃O₂S
• Molecular Weight: 261.29964
• Mol File: 857200-26-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(methylthio)-4-(phenylamino)pyrimidine-5-carboxylicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(methylthio)-4-(phenylamino)pyrimidine-5-carboxylicacid(857200-26-1)
• EPA Substance Registry System: 2-(methylthio)-4-(phenylamino)pyrimidine-5-carboxylicacid(857200-26-1)

Safety Data

• Hazardous Substances Data: 857200-26-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(methylthio)-4-(phenylamino)pyrimidine-5-carboxylic acid is used as a pharmaceutical agent for its potential inhibitory effects on specific enzymes and receptors. Its unique structure and properties contribute to its potential as a therapeutic compound in the development of new drugs for various medical conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-(methylthio)-4-(phenylamino)pyrimidine-5-carboxylic acid serves as a valuable compound for further research and development. Its ability to modulate biological targets makes it a candidate for the creation of novel therapeutic agents and the exploration of its potential applications in treating diseases and disorders.

Upstream product

• 74840-34-9 4-chloro-2-(methylsulfanyl)pyrimidine-5-carboxylic acid 
• 62-53-3 aniline 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 106475-47-2 2-methanesulfanyl-4-phenylamino-pyrimidine-5-carboxylic acid ethyl ester 

Downstream Products

• 1089723-99-8 C₁₂H₁₃N₅OS 
• 1315513-45-1 2-Methylsulfanyl-4-phenylamino-5-pyrimidinecarboxylic acid fluoride 
• 1315513-46-2 7-Amino-2-methylsulfanyl-5-oxo-8-phenyl-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide 
• 1315513-49-5 tert-Butyl 4-[4-(7-amino-6-carbamoyl-5-oxo-8-phenyl-5,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl]piperidine-1-carboxylate 
• 1315513-78-0 7-Amino-2-[2-methoxy-4-(1-methylpiperid-4-yl)phenylamino]-5-oxo-8-phenyl-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide 
• 1315513-84-8 7-Amino-2-[2-methoxy-4-(2-pyrrolidin-1-ylethyl)phenylamino]-5-oxo-8-phenyl-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide 
• 1315513-48-4 7-amino-2-methanesulfinyl-5-oxo-8-phenyl-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide 
• 1315513-47-3 7-amino-2-methanesulfonyl-5-oxo-8-phenyl-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide 
• 1253791-97-7 C₁₇H₁₅N₃O₄S 
• 1421367-68-1 2-(methylthio)-N-(3-(2-oxopyrrolidin-1-yl)propyl)-4-(phenylamino)pyrimidine-5-carboxamide 

Relevant articles and documents

Design and Development of a Chemical Probe for Pseudokinase Ca2+/calmodulin-Dependent Ser/Thr Kinase

CASK (Ca2+/calmodulin-dependent Ser/Thr kinase) is a member of the MAGUK (membrane-associated guanylate kinase) family that functions as neurexin kinases with roles implicated in neuronal synapses and trafficking. The lack of a canonical DFG motif, which

Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001

As a result of emerging biological data suggesting that within the c-Jun N-terminal kinase (JNK) family, JNK1 and not JNK2 or JNK3 may be primarily responsible for fibrosis pathology, we sought to identify JNK inhibitors with an increased JNK1 bias relative to our previous clinical compound tanzisertib (CC-930). This manuscript reports the synthesis and structure-activity relationship (SAR) studies for a novel series of JNK inhibitors demonstrating an increased JNK1 bias. SAR optimization on a series of 2,4-dialkylamino-pyrimidine-5-carboxamides resulted in the identification of compounds possessing low nanomolar JNK inhibitory potency, overall kinome selectivity, and the ability to inhibit cellular phosphorylation of the direct JNK substrate c-Jun. Optimization of physicochemical properties in this series resulted in compounds that demonstrated excellent systemic exposure following oral dosing, enabling in vivo efficacy studies and the selection of a candidate for clinical development, CC-90001, which is currently in clinical trials (Phase II) in patients with idiopathic pulmonary fibrosis (NCT03142191).

Substituted Tricyclic Pyrazolo-Pyrimidine Compounds

The present invention relates to substituted tricyclic pyrazolo-pyrimidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted tricyclic pyrazolo-pyrimidine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES

The present invention relates to 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives, to their preparation and to their therapeutic use.

PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF

A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors

5-(1,3,4-Oxadiazol-2-yl)pyrimidine derivative 1 was identified as a new class of FLT3 inhibitor from our compound library. With the aim of enhancement of antitumor activity of 2 prepared by minor modification of1, structure optimization of side chains at the 2-, 4-, and 5-positions of the pyrimidine ring of 2 was performed to improve the metabolic stability. Introduction of polar substituents on the 1,3,4-oxadiazolyl group contributed to a significant increase in the metabolic stability. As a result, a series of compounds showed increased efficacy against MOLM-13 xenograft model in mice by oral administration.